


Image

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-5.4DIV

In Re Application:

ANAND et al.



Serial No.

09/578,239

Filing Date

May 24, 2000

Examiner

Sonya N. Wright

Group Art Unit

1626

1-(4-ARYLPIPERAZIN-1-Y)-OMEGA-[N-(ALPHA, OMEGA-DICARBOXIMIDOL)]-ALKANES
URO-SELECTIVE ALPHA A1-ADRENORECEPTOR BLOCKERS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$180.00
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited January 27, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Kim Campbell

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

George E. Heibel

Signature

Dated:

1/28/04

George E. Heibel, PhD

Reg. No. 42,648

Ranbaxy Pharmaceuticals Inc.

600 College Road East, Suite 2100

Princeton, New Jersey 08540

Telephone: (609) 720-5334

Facsimile: (609) 514-9779

02/ 6/2004 HDAHTE1 00000053 500912 09578239

01 00000006 180.00 DA

1626


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-5.4DIV

In Re Application Of:

ANAND et al.



Serial No.
09/578,239

Filing Date
May 24, 2000

Examiner
Sonya N. Wright

Group Art Unit
1626

Title: 1-(4-ARYLPIPERAZIN-1-Y)-OMEGA-[N-(ALPHA, OMEGA-DICARBOXIMIDOL]-ALKANES
URO-SELECTIVE ALPHA A1-ADRENORECEPTOR BLOCKERS

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)


2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

INFORMATION DISCLOSURE CITATION Supplemental 1/28/04	Docket No.: RLL-5.4DIV	Serial No.: 09/578,239
	Applicants: ANAND <i>et al.</i>	
	Filed: 5/24/2000	Group: 1626



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2A1	4,216,216	8/5/1980	Weber <i>et al.</i>	424	251	
	2A2	4,479,954	10/30/1984	Hirose <i>et al.</i>	424	251	
	2A3	4,675,403	6/23/1987	Abou-Gharbia <i>et al.</i>	544	230	
	2A4	5,859,014	1/12/1999	Bantle <i>et al.</i>	514	255	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	2B1	AU 36788/78	1/6/1978	Australia	C07D	401/04		
	2B2	AU 45940/72	8/24/1972	Australia	C07D	51/70		
	2B3	CN 1149051	5/7/1997	China	C07D	413/12		X
	2B4	DE 2 242 382	8/29/1972	Germany	C07D	51/70		X
	2B5	EP 0 000 220	6/14/1978	EPO	C07D	403/00		
	2B6	EP 0 103 357	6/17/1983	EPO	C07D	233/72		
	2B7	EP 0 748 800	5/9/2001	EPO	C07D	239/54		
	2B8	ES 2 094 690	1/16/1997	Spain	C07D	207/45		X
	2B9	FR 2,179,491	11/23/1973	France	A61K	27/00		X
	2B10	GB 1 368 256	9/25/1974	UK	C07D	57/00		
	2B11	HU 211 910	6/29/1995	Hungary	C07D	295/10		X


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	2C1	Mokrosz <i>et al.</i> , "Structure-activity relationship studies of CNS agents. Part 32. Effect of structural modifications in 1-arylpiperazine derivatives on α 1-adrenoceptor affinity". <i>Arch Pharm.</i> (Weinheim, Germany) 330(6):177-180, (1997); Chemical Abstracts, Vol. 128, No 1; 128:128; RN 159311-94-1; CAPLUS Accession No. 1997:687574
	2C2	Chemical Abstracts, Vol. 107, No. 198046

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION Supplemental 1/28/04	Docket No.: RLL-5.4DIV	Serial No.: 09/578,239
	Applicants: ANAND <i>et al.</i>	
	Filed: 5/24/2000	Group: 1626



2C3	Chilmonczyk <i>et al.</i> , "Conformational flexibility of serotonin _{1A} receptor ligands from crystallographic data. Updated model of the receptor pharmacophore", <i>Chemical Abstracts</i> , Vol. 127, No. 27, 10/27/97
2C4	Database CAPLUS on STN International, Chemical Abstracts Service (Columbus, Ohio), Accession No. 1983:46453; YEVICH <i>et al.</i> <i>J.Med.Chem.</i> , 26(2) pp 194-203, abstract (1983)
2C5	DIMOGLO, A.S. <i>et al.</i> , "Study of Structure-Activity Relations in a Series of Buspirone Analogs Using an Electron-Topological Approach," <i>Khim.-Farm, Zh</i> , 381:36-40 (1998); <i>Chemical Abstracts</i> , Vol. 129, No. 3, 7/20/98; <i>Chemical Abstracts</i> 129:22916; ISSN: 0023-1134
2C6	HAYS, Sheryl J., "Synthesis of Carbon-14 Labeled CI-926 and CI-927, New Antihypertensives," <i>Chemical Abstracts</i> , Vol. 108, No. 3, 1/18/88
2C7	KENNY <i>et al.</i> , "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia," <i>Journal of Medicinal Chemistry</i> , 40(9):1292-1315 (1997)
2C8	KHADILKAR, B.M. <i>et al.</i> , "Synthesis and Hypotensive Activity of Some Succinimide Derivatives," <i>Chemical Abstracts</i> , Vol. 119, No. 3, 7/19/93
2C9	MOKROSZ, Jerzy <i>et al.</i> , "8-4'-2-(1,2,3,4-tetrahydroisoquinolyl)butyl-8-azaspiro 4,5 decane-7,9-dione: A new 5-HT _{1a} receptor ligand with the same activity profile as buspirone," <i>Journal of Medicinal Chemistry</i> , Vol. 5, No. 39, pp 1125-1129 1/1/96
2C10	MOKROSZ, Maria, "Structure-activity relationship studies of CNS agents", <i>Chemical Abstracts</i> , 121:291989x, p 24 (1994)
2C11	RYAN, M.J. <i>et al.</i> , "CI-926 (3-[4-[4-(3-Methylphenyl)-1-Piperazinyl]Butyl]-2,4-Imidazolinedione): Antihypertensive Profile and Pharmacology," <i>Chemical Abstracts</i> , Vol. 105, No. 19, 11/10/86

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	